Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Maintains $38 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Geulah Livshits maintains a Buy rating on 4D Molecular Therapeutics (NASDAQ:FDMT) with a $38 price target.

July 17, 2024 | 7:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital analyst Geulah Livshits maintains a Buy rating on 4D Molecular Therapeutics (NASDAQ:FDMT) with a $38 price target.
The reaffirmation of a Buy rating and a specific price target of $38 by Chardan Capital is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100